Heath Lukatch - Jan 31, 2024 Form 4 Insider Report for Vaxcyte, Inc. (PCVX)

Role
Director
Signature
Heath Lukatch, by /s/ Andrew Guggenhime, Attorney-in-Fact
Stock symbol
PCVX
Transactions as of
Jan 31, 2024
Transactions value $
-$277,500
Form type
4
Date filed
2/2/2024, 04:40 PM
Previous filing
Jan 31, 2024
Next filing
Jun 10, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction PCVX Common Stock Options Exercise $80K +5K +88.89% $16.00 10.6K Jan 31, 2024 Direct
transaction PCVX Common Stock Sale -$358K -5K -47.06% $71.50 5.63K Jan 31, 2024 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PCVX Stock Option (right to buy) Options Exercise $0 -5K -45.45% $0.00 6K Jan 31, 2024 Common Stock 5K $16.00 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on May 11, 2023.
F2 Fully vested and exercisable.